<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05019326</url>
  </required_header>
  <id_info>
    <org_study_id>MURA2021/652</org_study_id>
    <nct_id>NCT05019326</nct_id>
  </id_info>
  <brief_title>Andrographis Paniculata vs Boesenbergia Rotunda vs Control in Asymptomatic COVID-19</brief_title>
  <official_title>A Two-stage Adaptive Randomized Controlled Trial of Andrographis Paniculata Extract, Boesenbergia Rotunda Extract, and Standard Treatment in Asymptomatic COVID-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Thailand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effect of Andrographis Extract, Boesenbergia&#xD;
      Extract compared to standard treatment in asymptomatic COVID patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2021</start_date>
  <completion_date type="Anticipated">May 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Require hospitalization in the hospital</measure>
    <time_frame>28 days</time_frame>
    <description>From WHO clinical progression scale (0-10):&#xD;
0: Uninfected with no viral RNA detected&#xD;
Asymptomatic with viral RNA detected&#xD;
Symptomatic and independent&#xD;
Symptomatic with assistance needed&#xD;
Hospitalized with no oxygen therapy needed&#xD;
Hospitalized with oxygen mask or nasal prongs&#xD;
Hospitalized with oxygen by NIV or high flow&#xD;
Intubation and mechanical ventilation with pO2/FiO2 &gt;= 150 or SpO2/FiO2 &gt;= 200&#xD;
Mechanical ventilation with pO2/FiO2 &lt; 150 (SpO2/FiO2 &lt;200) or vasopressor&#xD;
Mechanical ventilation with pO2/FiO2 &lt; 150 and vasopressor, dialysis, or ECMO&#xD;
Dead&#xD;
Outcome 4 or more considered as hospitalization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Individual status from WHO clinical progression scale (0-10)</measure>
    <time_frame>28 days</time_frame>
    <description>From WHO clinical progression scale:&#xD;
0: Uninfected with no viral RNA detected&#xD;
Asymptomatic with viral RNA detected&#xD;
Symptomatic and independent&#xD;
Symptomatic with assistance needed&#xD;
Hospitalized with no oxygen therapy needed&#xD;
Hospitalized with oxygen mask or nasal prongs&#xD;
Hospitalized with oxygen by NIV or high flow&#xD;
Intubation and mechanical ventilation with pO2/FiO2 &gt;= 150 or SpO2/FiO2 &gt;= 200&#xD;
Mechanical ventilation with pO2/FiO2 &lt; 150 (SpO2/FiO2 &lt;200) or vasopressor&#xD;
Mechanical ventilation with pO2/FiO2 &lt; 150 and vasopressor, dialysis, or ECMO&#xD;
Dead&#xD;
More on the scale - worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumonia</measure>
    <time_frame>28 days</time_frame>
    <description>Pneumonia by diagnosis or chest radiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life by EQ5D-5L</measure>
    <time_frame>28 days</time_frame>
    <description>Quality of life by EQ5D-5L&#xD;
Scale of 0 to 100 for overall health state (lower is worse) and 1 to 5 in each of 5 domains. (higher score is worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effect of medication</measure>
    <time_frame>28 days</time_frame>
    <description>Renal and liver function elevation and other anticipated/unanticipated side effect:&#xD;
Side effect of medication will be classified according to common terminology criteria for adverse events (CTCAE) version 5.0</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">3060</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Andrographis extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Andrographis extract, equivalent to andrographolide 20 mg per capsule, for a total of 180 mg of andrographolide per day, dosing into 3 capsules taking before meal for 3 times per day, for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Boesenbergia extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Boesenbergia extract, equivalent to pinostrobin 30 mg per capsule, for a total of 180 mg of pinostrobin per day, dosing into 2 capsules taking after meal for 3 times per day for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard supportive treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard supportive treatment, as recommended by guideline from Ministry of Public Health, Thailand, there will be no antivirus given in this asymptomatic group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Andrographis Paniculata</intervention_name>
    <description>Andrographis extract, equivalent to andrographolide 20 mg per capsule, for a total of 180 mg of andrographolide per day, dosing into 3 capsules taking before meal for 3 times per day, for 5 days.</description>
    <arm_group_label>Andrographis extract</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Boesenbergia</intervention_name>
    <description>Boesenbergia extract, equivalent to pinostrobin 30 mg per capsule, for a total of 180 mg of pinostrobin per day, dosing into 2 capsules taking after meal for 3 times per day for 5 days.</description>
    <arm_group_label>Boesenbergia extract</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard supportive treatment</intervention_name>
    <description>as recommended by guidelines from the Ministry of Public Health, Thailand. No antivirus was given.</description>
    <arm_group_label>Standard supportive treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18- 60 years old&#xD;
&#xD;
          2. Have been diagnosed as new COVID-19 case by RT-PCR since disease onset to admission&#xD;
             less than 7 days&#xD;
&#xD;
          3. Have asymptomatic infection assessed by the World Health Organization (WHO) disease&#xD;
             category&#xD;
&#xD;
          4. Do not have any of following disease or conditions&#xD;
&#xD;
               1. Body weight &gt; 90 kg or BMI &gt; 30 kg/m2&#xD;
&#xD;
               2. Hypertension that needs antihypertensive medication&#xD;
&#xD;
               3. Diabetes&#xD;
&#xD;
               4. Cardiovascular diseases including congenital heart disease&#xD;
&#xD;
               5. Cerebrovascular diseases&#xD;
&#xD;
               6. Chronic kidney and chronic liver diseases&#xD;
&#xD;
               7. COPD or chronic lung diseases&#xD;
&#xD;
               8. Lymphocyte &lt;1,000 cells/mm3&#xD;
&#xD;
               9. Late-stage cancer&#xD;
&#xD;
              10. Auto-immune disease (e.g., SLE, Rheumatoid arthritis, multiple sclerosis, etc.)&#xD;
                  or currently on immunosuppressive drug&#xD;
&#xD;
              11. Coagulation disorders or platelet disorders and are being treated with&#xD;
                  anticoagulants such as warfarin, clopidogrel&#xD;
&#xD;
              12. Pregnancy&#xD;
&#xD;
          5. Willing to participate with the study and sign inform consents.&#xD;
&#xD;
        (Withdrawal criteria)&#xD;
&#xD;
          1. Patients withdraw from the study&#xD;
&#xD;
          2. Have severe adverse effect that may relate to Andographolide or Boesenbergia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pawin Numthavaj</last_name>
    <phone>+6622011284</phone>
    <email>pawin.num@mahidol.ac.th</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of Medicine Ramathibodi Hospital</name>
      <address>
        <city>Ratchathewi</city>
        <state>Bangkok</state>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pawin Numthavaj, MD</last_name>
      <phone>+6622011284</phone>
      <email>pawin.num@mahidol.ac.th</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 21, 2021</study_first_submitted>
  <study_first_submitted_qc>August 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2021</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment</keyword>
  <keyword>Andrographis</keyword>
  <keyword>Boesenbergia</keyword>
  <keyword>Covid19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Andrographolide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>May shared IPD upon sponsor decision.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

